Surrozen, Inc./DE Fair Value Adjustment of Warrants
Surrozen, Inc./DE (SRZN) reported Fair Value Adjustment of Warrants of $20.75 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-06
- Surrozen, Inc./DE fair value adjustment of warrants for the quarter ending 2026-06-30 was -$20.36M.
- Surrozen, Inc./DE fair value adjustment of warrants for the quarter ending 2026-03-31 was $41.11M.
- Surrozen, Inc./DE fair value adjustment of warrants for the quarter ending 2025-12-31 was $58.60M, a 197.75% increase year-over-year.
- Surrozen, Inc./DE fair value adjustment of warrants for the quarter ending 2025-09-30 was $20.92M, a 556.95% increase year-over-year.
- Surrozen, Inc./DE fair value adjustment of warrants for fiscal 2025 was $22.83M, a 28.03% increase from fiscal 2024.
- Surrozen, Inc./DE fair value adjustment of warrants for fiscal 2024 was $17.83M.
- Surrozen, Inc./DE fair value adjustment of warrants for fiscal 2023 was -$211.00K.
- Surrozen, Inc./DE fair value adjustment of warrants for fiscal 2022 was -$7.89M.
| Period end | Fair Value Adjustment of Warrants 1 month | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 3 month as first filed | Fair Value Adjustment of Warrants 4 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 6 month as first filed | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$20.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $20.75M 10-Q · filed 2026-08-06 | $79.35M derived: sum of 3 quarters · filed 2026-08-06 | $100.28M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $41.11M 10-Q · filed 2026-05-06 | $99.71M derived: sum of 2 quarters · filed 2026-05-06 | $120.64M derived: sum of 3 quarters · filed 2026-05-06 | $104.56M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $58.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $79.53M derived: sum of 2 quarters · filed 2026-03-23 | $63.45M derived: sum of 3 quarters · filed 2026-08-06 | $22.83M 10-K · filed 2026-03-23 | ||||
| 2025-09-30 | $20.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $4.85M derived: sum of 2 quarters · filed 2026-08-06 | -$35.77M 10-Q · filed 2025-11-07 | -$16.09M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | -$16.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$56.70M 10-Q · filed 2026-08-06 | -$37.02M derived: sum of 3 quarters · filed 2026-08-06 | -$33.83M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | -$40.62M 10-Q · filed 2026-05-06 | -$20.94M derived: sum of 2 quarters · filed 2026-05-06 | -$17.76M derived: sum of 3 quarters · filed 2026-05-06 | -$22.86M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $19.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $22.87M derived: sum of 2 quarters · filed 2026-03-23 | $17.77M derived: sum of 3 quarters · filed 2026-03-23 | $17.83M 10-K · filed 2026-03-23 | ||||
| 2024-10-31 | $2.60M 10-K · filed 2026-03-23 | |||||||
| 2024-09-30 | $3.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$1.91M derived: sum of 2 quarters · filed 2025-11-07 | -$1.85M 10-Q · filed 2025-11-07 | -$1.98M derived: sum of 4 quarters · filed 2025-11-07 | ||||
| 2024-06-30 | -$5.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | -$5.04M 10-Q · filed 2025-08-08 | -$5.16M derived: sum of 3 quarters · filed 2025-08-08 | -$5.25M derived: sum of 4 quarters · filed 2025-08-08 | ||||
| 2024-04-30 | $37.90M 10-K · filed 2026-03-23 | |||||||
| 2024-03-31 | $63.00K 10-Q · filed 2025-05-09 | -$65.00K derived: sum of 2 quarters · filed 2025-05-09 | -$148.00K derived: sum of 3 quarters · filed 2025-05-09 | -$413.00K derived: sum of 4 quarters · filed 2025-05-09 | ||||
| 2023-12-31 | -$128.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$211.00K derived: sum of 2 quarters · filed 2025-03-31 | -$476.00K derived: sum of 3 quarters · filed 2025-03-31 | -$211.00K 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | -$83.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$348.00K derived: sum of 2 quarters · filed 2024-11-06 | -$83.00K 10-Q · filed 2024-11-06 | -$1.00M derived: sum of 4 quarters · filed 2024-11-06 | ||||
| 2023-06-30 | -$265.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $0.00 10-Q · filed 2024-08-12 | -$921.00K derived: sum of 3 quarters · filed 2024-08-12 | -$971.00K derived: sum of 4 quarters · filed 2024-08-12 | ||||
| 2023-03-31 | $265.00K 10-Q · filed 2024-05-08 | -$656.00K derived: sum of 2 quarters · filed 2024-05-08 | -$706.00K derived: sum of 3 quarters · filed 2024-05-08 | -$1.13M derived: sum of 4 quarters · filed 2024-05-08 | ||||
| 2022-12-31 | -$921.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-10 | -$971.00K derived: sum of 2 quarters · filed 2024-04-10 | -$1.39M derived: sum of 3 quarters · filed 2024-04-10 | -$7.89M 10-K · filed 2024-04-10 | ||||
| 2022-09-30 | -$50.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$472.00K derived: sum of 2 quarters · filed 2023-11-08 | -$6.97M 10-Q · filed 2023-11-08 | -$6.98M derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2022-06-30 | -$422.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$6.92M 10-Q · filed 2023-08-09 | -$6.93M derived: sum of 3 quarters · filed 2023-08-09 | -$6.99M derived: sum of 4 quarters · filed 2023-08-09 | ||||
| 2022-03-31 | -$6.50M 10-Q · filed 2023-05-10 | -$6.50M derived: sum of 2 quarters · filed 2023-05-10 | -$6.57M derived: sum of 3 quarters · filed 2023-05-10 | -$4.03M derived: sum of 4 quarters · filed 2023-05-10 | ||||
| 2021-12-31 | -$7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$71.00K derived: sum of 2 quarters · filed 2023-03-31 | $2.47M derived: sum of 3 quarters · filed 2023-03-31 | -$71.00K 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | -$64.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $2.47M derived: sum of 2 quarters · filed 2022-11-14 | -$64.00K 10-Q · filed 2022-11-14 | $2.47M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | $2.54M 10-Q · filed 2021-08-09 | $0.00 10-Q · filed 2022-08-11 | $1.73M 10-Q · filed 2021-08-09 | $2.54M derived: sum of 3 quarters · filed 2022-05-11 | ||||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-11 | -$802.83K 10-Q · filed 2021-05-24 | $0.00 derived: sum of 2 quarters · filed 2022-05-11 | |||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $1.57M 10-K/A · filed 2021-05-14 | $0.00 10-K · filed 2022-03-28 | |||||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |